clinical trial · NCT04348136
An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II
JCR Pharmaceuticals Co., Ltd.·phase3·active not recruiting·n = 27
Mucopolysaccharidosis IIJR-141
brief summary
Multicenter, open-label, single-group, designed to evaluate the long term efficacy and safety of study drug for the treatment of the MPS II.
started
Sep 1, 2019
primary completion
Mar 31, 2030
completion
Mar 31, 2030
last updated
Jul 24, 2025
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol